Concerto HealthAI to Present AI Model for Predicting Survival of Lung Cancer Patients, with Wide-Ranging Uses for Clinical Development

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Concerto HealthAI to Present AI Model for Predicting Survival of Lung Cancer Patients, with Wide-Ranging Uses for Clinical Development

Research on AI model to be presented at ASCO 2019 Annual Meeting; useful for assessing patient risk and treatment options, evaluating cost and quality of care or determining trial eligibility

PR Newswire

BOSTON, May 28, 2019 /PRNewswire-PRWeb/ -- Concerto HealthAI announced today that it has developed an AI model predicting survival of lung cancer patients 3-12 months from their last clinical visit. The model allows clinical researchers to gain deeper insights into key variables impacting patient survival. This model will be presented as a research abstract during a poster session at the 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, on June 1, from 1:15-4:15 p.m.

The Gradient Boosting model was built using de-identified structured data from 55,000 lung cancer patients in ASCO's CancerLinQ Discovery database. Nearly 4,000 unique variables, including diagnostic and therapeutic codes, biomarkers, surgeries and lab tests, were accessible to the model. Model validation was done on a randomly selected and reserved set of 8,468 patients. Results were significantly better than a baseline Cox-PH model and compared very favorably to other survival models in the literature created using AI and comparable machine learning techniques.

"A model that can accurately predict risk of mortality in patients at various time points could help guide clinical development teams to more effectively select attributes of patients for different pre- and post-approval studies to bring needed new therapies forward and enhance the effectiveness of existing therapies respectively," said Smita Agrawal, Ph.D. and Senior Director of Product Management at Concerto HealthAI and the research abstract's primary author. "This could have a huge impact on the accessibility of new treatments and overall costs of care."

"There are enormous costs associated with every patient recruited into a clinical trial," said Jeff Elton, Ph.D. and CEO of Concerto HealthAI. "The stakes are high but researchers just haven't had the tools to give them the insights to change how they work and design trials with speed and efficiency. Researchers can now determine with a high degree of confidence which patients are expected to survive the next three months and recruit accordingly to ensure a successful clinical trial at a faster pace. This class of Concerto HealthAI models have immense positive implications for both the patient entering the trial and for clinical trial researchers designing those studies."

About Concerto HealthAI

Concerto HealthAI is a technology leader in Definitive Real-world Data (RWD) and AI solutions for precision oncology. Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent. Our focus is to revolutionize clinical and outcomes research to accelerate the insights and outcomes benefitting patient treatment. Concerto HealthAI is a SymphonyAI company. eurekaHealth is a trademark of Concerto HealthAI. For more information, visit us at https://www.concertohealthai.com.

 

SOURCE Concerto HealthAI

Copyright CNW Group 2019

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).